Antidepressant-like properties of the anti-Parkinson agent, piribedil, in rodents: mediation by dopamine D2 receptors
Authors:
- Mauricette BroccoMBMauricette Brocco
- Anne DekeyneADAnne Dekeyne
- Mariusz PappMPMariusz Papp
- Mark J. MillanMMMark J. Millan
- 1 November 2006
- journal article
- Published by Wolters Kluwer Health in Behavioural Pharmacology
- Vol. 17 (7) , 559-572
Abstract
The dopamine D2/D3 receptor agonist and α2 adrenergic receptor antagonist, piribedil, is used clinically as monotherapy and as an adjunct to L-3,4-dihydroxyphenylalanine in the treatment of Parkinson's disease. As it appears to improve mood, we examined its actions in rodent models of antidepressant properties, in comparison with the prototypical anti-Parkinson agent, apomorphine, the D2/D3 receptor agonist, quinpirole, and the antidepressants, imipramine and fluvoxamine. In the mouse forced-swim test, acute administration of imipramine, fluvoxamine, apomorphine or quinpirole decreased immobility time, actions dose dependently mimicked by piribedil (2.5–10.0 mg/kg, subcutaneously). In rats, acute and subchronic administration of piribedil similarly reduced immobility (0.63–10.0 mg/kg, subcutaneously) and apomorphine, quinpirole and imipramine were also active in this test, whereas fluvoxamine was inactive. Both in mice and in rats, the D2/D3 receptor antagonist, raclopride, and the D2 receptor antagonist, L741,626, dose dependently blocked the antidepressant properties of piribedil, whereas the selective D3 receptor antagonists, S33084 and SB277,011, were ineffective. In a chronic mild stress model in rats, piribedil (2.5–40.0 mg/kg, subcutaneously) restored sucrose intake in stressed animals exerting its actions more rapidly (by week 1) than imipramine. Imipramine, fluvoxamine, apomorphine, quinpirole and piribedil dose dependently (0.63–10.0 mg/kg, subcutaneously) suppressed aggressive and marble-burying behaviour in mice. In the latter procedure, raclopride and L741,626, but not S33084, attenuated the actions of piribedil. Over a dose range (0.63–10.0 mg/kg, subcutaneously) equivalent to those active in models of antidepressant activity, piribedil did not stimulate locomotor behaviour. In conclusion, principally via recruitment of D2 receptors, piribedil exerts robust and specific antidepressant-like actions in diverse rodent models.Keywords
This publication has 99 references indexed in Scilit:
- Par-4 Links Dopamine Signaling and DepressionCell, 2005
- Anhedonia, Depression, and Motor Functioning in Parkinson's Disease During Treatment With PramipexoleThe Journal of Neuropsychiatry and Clinical Neurosciences, 2005
- End‐of‐dose akinesia after a single intravenous infusion of the dopaminergic agonist piribedil in Parkinson's disease patients: A pharmacokinetic/pharmacodynamic, randomized, double‐blind studyMovement Disorders, 2005
- Levodopa-induced dyskinesia in Parkinson?s diseaseJournal of Neural Transmission, 2004
- Dopamine agonists in Parkinson’s diseaseExpert Opinion on Investigational Drugs, 2003
- Efficacy of piribedil as early combination to levodopa in patients with stable Parkinson's disease: A 6‐month, randomized, placebo‐controlled studyMovement Disorders, 2003
- Differential Actions of Antiparkinson Agents at Multiple Classes of Monoaminergic Receptor. III. Agonist and Antagonist Properties at Serotonin, 5-HT1 and 5-HT2, Receptor SubtypesThe Journal of Pharmacology and Experimental Therapeutics, 2002
- RopiniroleDrugs, 2000
- EditorialJournal of Psychopharmacology, 1996
- Quinpirole hydrochloride, a potential anti-parkinsonism drugNeuropharmacology, 1987